share_log
Breakings ·  Sep 28 06:00
BridgeBio: Attribute-Cm Study Shows 42% Cut in Composite ACM and Recurrent Cvh Events at 30 Months Observed With Acoramidis Treatment Vs Placebo
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment